What's in Immune Response BioPharma, Inc.'s pipeline?

Immune Response BioPharma, Inc. has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Immune Response BioPharma, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/immune-response-biopharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Immune Response BioPharma, Inc. — Portfolio Competitive Intelligence Brief

Immune Response BioPharma, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
IR103	IR103	phase 3			Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Immune Response BioPharma, Inc.:

Cite this brief

Drug Landscape (2026). Immune Response BioPharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/immune-response-biopharma-inc. Accessed 2026-05-16.